Amphastar Pharmaceuticals Inc (AMPH)
42.64
+0.60
(+1.43%)
USD |
NASDAQ |
May 02, 16:00
42.64
0.00 (0.00%)
After-Hours: 19:50
Amphastar Pharmaceuticals Enterprise Value: 2.355B for May 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 01, 2024 | 2.355B |
April 30, 2024 | 2.317B |
April 29, 2024 | 2.354B |
April 26, 2024 | 2.310B |
April 25, 2024 | 2.297B |
April 24, 2024 | 2.305B |
April 23, 2024 | 2.301B |
April 22, 2024 | 2.265B |
April 19, 2024 | 2.258B |
April 18, 2024 | 2.192B |
April 17, 2024 | 2.259B |
April 16, 2024 | 2.300B |
April 15, 2024 | 2.295B |
April 12, 2024 | 2.239B |
April 11, 2024 | 2.264B |
April 10, 2024 | 2.259B |
April 09, 2024 | 2.300B |
April 08, 2024 | 2.308B |
April 05, 2024 | 2.343B |
April 04, 2024 | 2.330B |
April 03, 2024 | 2.350B |
April 02, 2024 | 2.369B |
April 01, 2024 | 2.422B |
March 28, 2024 | 2.445B |
March 27, 2024 | 2.426B |
Date | Value |
---|---|
March 26, 2024 | 2.411B |
March 25, 2024 | 2.432B |
March 22, 2024 | 2.435B |
March 21, 2024 | 2.475B |
March 20, 2024 | 2.451B |
March 19, 2024 | 2.477B |
March 18, 2024 | 2.394B |
March 15, 2024 | 2.404B |
March 14, 2024 | 2.410B |
March 13, 2024 | 2.428B |
March 12, 2024 | 2.457B |
March 11, 2024 | 2.440B |
March 08, 2024 | 2.530B |
March 07, 2024 | 2.582B |
March 06, 2024 | 2.561B |
March 05, 2024 | 2.610B |
March 04, 2024 | 2.578B |
March 01, 2024 | 2.556B |
February 29, 2024 | 2.573B |
February 28, 2024 | 2.966B |
February 27, 2024 | 3.000B |
February 26, 2024 | 2.983B |
February 23, 2024 | 2.902B |
February 22, 2024 | 2.830B |
February 21, 2024 | 2.797B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
593.31M
Minimum
Mar 20 2020
3.514B
Maximum
Aug 08 2023
1.416B
Average
1.008B
Median
May 22 2019
Enterprise Value Benchmarks
Eli Lilly and Co | 761.94B |
Dentsply Sirona Inc | 8.041B |
Pacira BioSciences Inc | 1.497B |
Organon & Co | 12.88B |
NovaBay Pharmaceuticals Inc | 2.654M |
Enterprise Value Related Metrics
Net Income (Quarterly) | 36.17M |
Revenue (Quarterly) | 178.10M |
Total Expenses (Quarterly) | 124.12M |
EPS Diluted (Quarterly) | 0.68 |
Gross Profit Margin (Quarterly) | 53.98% |
Profit Margin (Quarterly) | 20.31% |
Earnings Yield | 6.05% |
Operating Earnings Yield | 8.72% |
Normalized Earnings Yield | 6.051 |